REG - AstraZeneca PLC - Annual Financial Report <Origin Href="QuoteRef">AZN.L</Origin> - Part 16
08/03/2016 12:11
- Part 16: For the preceding part double click ID:nRSH4027Ro
payers to limit the use of branded products and put pressure on
manufacturers to reduce net prices. In addition, payers are shifting a
greater proportion of the cost of branded medicines to the patient via
out-of-pocket payments at the pharmacy counter. The patient out-of-pocket
spend is generally in the form of a co-payment or, in some cases, a co
-insurance, which is designed, principally, to encourage patients to use
generic medicines.In Emerging Markets, governments are increasingly
controlling pricing in the self-pay sector and favouring locally
manufactured drugs.A summary of the principal aspects of price regulation
and how pricing pressures are affecting our business in our most
important markets is set out in Pricing of medicines in the Marketplace
section on page 14 and overleaf in the following risk factor. Economic,
- More to follow, for following part double click ID:nRSH4027RqRecent news on AstraZeneca
See all newsREG - AstraZeneca PLC - Tozorakimab met OBERON/TITANIA primary endpoints
AnnouncementREG - AstraZeneca PLC - Notification of Admission of Shares
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in EU for early gastric cancer
AnnouncementREG - AstraZeneca PLC - Notice of AGM
AnnouncementRCS - Redx Pharma Limited - RXC008 Receives US FDA Fast Track Designation
Announcement